FAQ: Which US public health concerns cystatin C testing help alleviate?

04. Mar 2020 | 5 min read

FAQ: Which US public health concerns cystatin C testing help alleviate?


In this segment we will answer questions our Product Manager for cystatin C and Product Specialist in the US get about cystatin C at exhibitions, conferences and client meetings. Today’s question is “
Which US public health concerns can cystatin C testing help alleviate?".

Which US public health concerns can cystatin C testing help alleviate?


Chronic kidney disease (CKD) is a growing public health issue with an estimated prevalence of 15% among U.S adults [1].  The high cost of treating end stage renal disease (ESRD) suggests that slowing CKD progression and developing targeted approaches to disease management should be a priority for healthcare systems in the US. Cystatin C testing could ensure that these priorities are met by enabling an unbiased assessment of renal function, which is central to diagnosis and management of kidney disease. In fact, cystatin C has been used to define a preclinical period of reduced kidney function that precedes conventional creatinine-based diagnosis of CKD by 10+ years [2,3].

Incorporating cystatin C testing into CKD patient care could also alleviate racial disparities in kidney disease outcomes, by allowing for assessment of renal function independent of a patient’s muscle mass. One such disparity is that African Americans who are diagnosed with CKD are three times as likely as Caucasians to develop ESRD [4]. Bias inherent in equations used to estimate kidney function solely via creatinine is a significant contributor to this public health issue.

The CKD-EPI equation regarded as the “best overall index for kidney function,” accounts for the higher muscle mass observed in African Americans with a 15.9% increase in eGFR over that of their Caucasians counterparts [5]. For a patient with below-average muscle mass, such an increase could delay diagnosis of CKD and interventions against progression into ESRD. In later stages of the disease, a 15.9% increase could also mean that an African American patient becomes eligible for dialysis or a kidney transplant much later than a Caucasian patient with the same prognosis.

 

Contact us

Do you want to know more about Gentian's cystatin C immunoassay or cystatin C in general? Send an email to marketing@gentian.com or fill out the form below and our Product Manager for cystatin C will get in touch.

 

FAQ about cystatin C

What type of antibodies are used in Gentian’s Cystatin C Immunoassay?

What are the advantages of measuring cystatin C in addition to creatinine?

Which patient populations would benefit from cystatin C testing?

What type of assay is the Gentian Cystatin C Immunoassay?

 

Cystatin C immunoassay brochure



References: 

  1. Chronic Kidney Disease in the United States, 2019. (2019, March 11). Retrieved April 28, 2020, from https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
  2. Shlipak MG et al. (2013). Cystatin C versus creatinine in determining risk based on kidney function. New England Journal of Medicine, 369(10), 932-943.
  3. Parsons T. (2013, September 4). Relationship of Kidney Function Estimates to Risk Improves by Measuring Cystatin C in the Blood. Retrieved April 6, 2020, from: https://www.jhsph.edu/news/news-releases/2013/coresh-cystatin-c.html
  4. HEALTHCARE, A. D. I. (2017). Chronic kidney disease in African Americans: Puzzle pieces are falling into place. Cleveland Clinic journal of medicine84(11), 855.
  5. Levey AS et al. (2009). A new equation to estimate glomerular filtration rate. Annals of internal medicine150(9), 604-612.

Gentian Cystatin C 

Gentian’s cystatin C immunoassay was launched in 2006. It is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro testing of cystatin C in human plasma and serum samples. The test has documented high inter-instrument accuracy on a wide range of clinical chemistry analysers and can be performed in as little as 10 minutes.

 

You may also read


Diagnostic Efficiency - October 2021

Oct 14, 2021

Diagnostic Efficiency - October 2021

Diagnostic efficiency - Newsletter October 2021 Gentian is very pleased that we again can present our..

NKF-ASN Task Force: Recommends increased use of cystatin C

Sep 24, 2021

NKF-ASN Task Force: Recommends increased use of cystatin C

NKF-ASN Task Force: Recommends increased use of cystatin C as a confirmatory assessment of GFR The NKF-ASN..

Cystatin C at AACC 2021

Sep 21, 2021

Cystatin C at AACC 2021

Meet us at #2021 AACC - Booth #2741 For its fifth consecutive year, Gentian Diagnostics will be participating..